Cisplatin (Platinol)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV, intracavitary (intraperitoneal)
Extravasation: vesicant (concentration ≥0.5 mg/mL)/irritant (concentration less than 0.5 mg/mL)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1978-12-19: Initial FDA approval
  • 2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. (No supporting studies are cited)
  • 2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. (Based on Wiernik et al. 1992a)
  • 2010-09-02 (oldest label available at Drugs @ FDA): PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy. (Based on Wiernik et al. 1992a)
  • 2010-09-02 (oldest label available at Drugs @ FDA): Indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. (No supporting studies are cited)

History of changes in EMA indication

  • 1978-12-19: EURD

History of changes in PMDA indication

Also known as

  • Code name: NSC-119875
  • Generic names: CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
  • Brand names:
Synonyms
Abiplatin Axiplat Biocisplatinum Bioplatino Blastolem Briplatin Brisplatin C-Platin
Ceplatin Ciplatan Ciplexal Cis-GRY Cismaplat Cispatin Cisplamerck Cisplan
Cisplasol Cisplatex Cisplatine Cisplatino Cisplatyl Cisteen Citoplatino Citosin
Cysplatyna Cytoplatin Docistin Elvecis Fauldcispla Ifapla Kemoplat Lederplatin
Metaplatin Neoplat Neoplatin Noveldexis Oncoplatin AQ Peyrone's Chloride Peyrone's Salt Placis
Plastistil Platamin Platamine Platiblastin Platicis Platidiam Platikem Platil
Platimit Platin Platinex Platinil Platino II Filaxis Platinol Platinox Platinoxan
Platiran Platistil Platistin Platistine Platosin Randa Romcis Sicatem
Sinplatin Sisplanil Tecnoplatin Tisplal Unistin

References

  1. ↑ 1.0 1.1 1.2 Cisplatin (Platinol) package insert
  2. ↑ Cisplatin (Platinol) package insert (locally hosted backup)
  3. ↑ Cisplatin (Platinol) patient drug information (Chemocare)
  4. ↑ Cisplatin (Platinol) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Cisplatin_(Platinol)&oldid=77647"